Baker Bros. Advisors LP Celldex Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 247,644 shares of CLDX stock, worth $4.53 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
247,644
Previous 247,644
-0.0%
Holding current value
$4.53 Million
Previous $8.41 Million
25.62%
% of portfolio
0.07%
Previous 0.09%
Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
199Shares Held
60.8MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$92.7 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$71 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$68.7 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$65.1 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $856M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...